A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

Completed · Phase 4

Conditions studied: Genital Herpes

In brief

The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.

Key facts

Study ID

NCT00129818

Run by

Novartis

Starts

2004-07-01

Expected to finish

2005-10-01

Last updated by the study team

2012-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

You may not qualify if…

• Pregnancy
• History of renal dysfunction
• Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
• Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• IU Center for Clinical STD Research — Indianapolis, Indiana, United States
• UNC Clinical Research - Raleigh — Raleigh, North Carolina, United States
• Lynne Health Science Institute — Oklahoma City, Oklahoma, United States
• Westover Heights Clinic — Portland, Oregon, United States
• University of Washington - Virology Research Clinic — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.